Decisional tool to assess current and future process robustness in an antibody purification facility

Biotechnology Progress

Volumn 28, Issue 4, 2012, Pages 1019-1028

  Stonier, Adam ^a,b   Simaria, Ana Sofia ^a   Smith, Martin ^b   Farid, Suzanne S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONZA AG   (Switzerland)

Author keywords

Antibody purification; Biopharmaceutical manufacture; Chromatography; MySQL database; Process economics; Stochastic discrete event simulation

Indexed keywords

ANTIBODY PURIFICATION; BIOPHARMACEUTICAL MANUFACTURE; DISCRETE EVENTS; MYSQL DATABASE; PROCESS ECONOMICS;

CELL CULTURE; CHROMATOGRAPHY; COMPUTER SIMULATION; DATABASE SYSTEMS; MONOCLONAL ANTIBODIES; OPTIMIZATION; UNCERTAINTY ANALYSIS; VISUALIZATION;

PURIFICATION;

ANTIBODY;

ARTICLE; BIOTECHNOLOGY; CHROMATOGRAPHY; CULTURE TECHNIQUE; ECONOMICS; EVALUATION; FILTRATION; INSTRUMENTATION; ISOLATION AND PURIFICATION; METHODOLOGY;

ANTIBODIES; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CHROMATOGRAPHY; FILTRATION;

EID: 84864864637     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1569     Document Type: Article

References (15)

1. Farid SS, Washbrook J, Titchener-Hooker NJ. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog. 2005; 21: 486-497.
2. Jagschies G. Where is biopharmaceutical manufacturing heading? Biopharm Int. 2008; 21: 72-75.
3. Kamarck ME. Building biomanufacturing capacity-the chapter and verse. Nat Biotechnol. 2006; 24: 503-505.
4. Davies J, Smith M, Bonnerjea J. The influence of scale of operation on purification process design. In: Proceedings of 154th Society for General Microbiology Meeting, 29 March-2 April, Bath, UK; 2004.
5. Sommerfeld S, Strube J. Challenges in biotechnology production-generic processes and process optimization for monoclonal antibodies. Chem Eng Process. 2005; 44: 1123-1137.
6. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog. 2007; 23: 995-1008.
7. Farid SS. Process economic drivers in industrial monoclonal antibody manufacture. In: Gottschalk U, editor. Process Scale Purification of Antibodies, Vol. 12. NJ: Wiley; 2009: 239-261.
8. Aldington S, Bonnerjea J. Scale-up of monoclonal antibody purification processes. J Chromatogr B. 2007; 848: 64-78.
9. Arunakumari A, Wang J, Ferreira G. Advances in non-protein a purification processes for human monoclonal antibodies. Biopharm Int. 2009; March; 22-26.
10. Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatogr B Anal Technol Biomed Life Sci. 2007; 848: 48-63.
11. Joseph JR, Sinclair A, Titchener-Hooker NJ, Zhou YH. A framework for assessing the solutions in chromatographic process design and operation for large-scale manufacture. J Chem Technol Biotechnol. 2006; 81: 1009-1020.
12. Farid SS, Washbrook J, Titchener-Hooker NJ. Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty. Biotechnol Prog. 2005; 21: 1183-1191.
13. Lim AC, Washbrook J, Titchener-Hooker NJ, Farid SS. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol Bioeng. 2006; 93: 687-697.
14. Lim AC, Zhou Y, Washbrook J, Sinclair A, Fish B, Francis R, Titchener-Hooker NJ, Farid SS. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnol. Prog. 2005; 21: 1231-1242.
15. Ho SV, McLaughlin JM, Cue BW, Dunn PJ. Environmental consideration in biologics manufacturing. Green Chem. 2010; 12: 755-766.